Skip to main content

Table 1 Patient characteristics

From: Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Patient Site subsite TNM stage elective dose (Gy) chemotherapy
1 oropharynx tonsil T4N2b IV 57.75 TPF + carbo weekly
2 oropharynx base of tongue T3N0 III 57.75 CDDP 3x
3 oropharynx tonsil T3N0 III 57.75 cetuximab
4 oropharynx tonsil T2N2b IV 57.75 CDDP weekly
5 oropharynx tonsil T4bN0 IV 57.75 TPF + CDDP weekly
6 oropharynx base of tongue T3N2b IV 57.75 CDDP 3x
7 oropharynx tonsil T3N1 III 57.75 CDDP 3x
8 oropharynx tonsil T2N2b IV 57.75 CDDP 3x
9 oropharynx pharyngeal wall T3N2b IV 57.75 CDDP 3x
10 oropharynx tonsil T3N2b IV 57.75 CDDP 3x
11 oropharynx tonsil T2N2b IV 57.75 CDDP 3x
12 oropharynx base of tongue T2N1 III 57.75 CDDP 3x
13 oropharynx tonsil T4N1 IV 57.75 TPF + carbo weekly
14 oropharynx base of tongue T3N0 III 57.75 cetuximab
15 larynx supraglottis T3N1 III 57.75 CDDP weekly
16 larynx supraglottis T3N0 III 57.75 CDDP 3x
17 larynx supraglottis T4N0 IV 57.75 CDDP 3x
18 larynx supraglottis T3N0 III 57.75 CDDP 3x
19 hypopharynx postcricoid T3N2c IV 57.75 CDDP 3x
20 hypopharynx piriform sinus T4aN2b IV 57.75 CDDP 3x
21 hypopharynx piriform sinus T4N2b IV 57.75 CDDP 3x
22 oropharynx tonsil T2N0 II 54.25  
23 oropharynx base of tongue T1N1 III 54.25  
24 oropharynx tonsil T2N0 II 54.25  
25 oropharynx base of tongue T3N0 III 54.25  
26 oropharynx soft palate T2N1 III 54.25  
27 oropharynx soft palate T1N0 I 54.25  
28 larynx transglottis T2N2b IV 54.25  
29 larynx glottis T3N0 III 54.25  
30 larynx supraglottis T2N0 II 54.25  
31 hypofarynx piriform sinus T2N1 III 54.25  
  1. CDDP: cisplatinum
  2. CDDP 3x: 3 cycles of cisplatinum 100 mg/m2
  3. TPF: docetaxel 75 mg/m2 day 1, cisplatinum 75 mg/m2day 1, 5-FU 750 mg/m2 day 1-5